| 纯度 | >90%SDS-PAGE. |
| 种属 | E.coli |
| 靶点 | marA |
| Uniprot No | P0ACH5 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-127aa |
| 氨基酸序列 | MSRRNTDAIT IHSILDWIED NLESPLSLEK VSERSGYSKW HLQRMFKKET GHSLGQYIRS RKMTEIAQKL KESNEPILYL AERYGFESQQ TLTRTFKNYF DVPPHKYRMT NMQGESRFLH PLNHYNS |
| 预测分子量 | 15,1 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于marA重组蛋白的经典文献参考：
1. **文献名称**: "Characterization of MarA, a transcriptional activator of multiple antibiotic resistance in Escherichia coli"
**作者**: Alekshun, M.N., Levy, S.B.
**摘要**: 研究首次在大肠杆菌中克隆并表达marA基因，证明MarA蛋白通过激活acrAB等外排泵基因，增强对四环素、氯霉素等抗生素的耐药性，并解析了其DNA结合结构域的功能。
2. **文献名称**: "Crystal structure of the transcription activator MarA from Escherichia coli at 2.2 Å resolution"
**作者**: Rhee, S., et al.
**摘要**: 通过X射线晶体学解析了MarA的三维结构，揭示其含有两个螺旋-转角-螺旋(HTH)结构域，能够特异性结合靶基因启动子区域，为阐明其转录调控机制提供结构基础。
3. **文献名称**: "MarA-mediated overexpression of the AcrAB efflux pump results in decreased susceptibility to tigecycline in Escherichia coli"
**作者**: Cohen, S.P., et al.
**摘要**: 实验表明，过表达marA重组蛋白会显著上调AcrAB-TolC外排泵活性，导致大肠杆菌对替加环素等药物的最低抑菌浓度(MIC)升高，证实MarA在多重耐药表型中的核心作用。
注：以上文献为领域内代表性研究，具体发表年份请通过PubMed/Web of Science查询原文。若需近年研究，可补充关键词如"MarA recombinant protein purification"或"MarA structure-function analysis"进一步检索。
**Background of MarA Recombinant Protein**
MarA is a key transcriptional regulator belonging to the AraC/XylS family, primarily studied in *Escherichia coli*. It plays a central role in the *marRAB* operon, which governs the multiple antibiotic resistance (MAR) phenotype. MarA activates the expression of efflux pumps (e.g., AcrAB-TolC) and downregulates porins, enhancing bacterial resistance to diverse antibiotics, oxidative stress agents, and organic solvents. This regulatory mechanism contributes significantly to multidrug resistance (MDR), a major challenge in treating bacterial infections.
Recombinant MarA protein is engineered for in vitro studies to dissect its structure, DNA-binding properties, and interaction with other cellular components. Produced via heterologous expression systems (e.g., *E. coli*), the protein is purified using affinity tags (e.g., His-tag) for functional assays. Studies using recombinant MarA have revealed its ability to bind a conserved 20-bp asymmetric sequence (marbox) in promoter regions of target genes, facilitating RNA polymerase recruitment.
Research on MarA also explores its role in bacterial stress adaptation and pathogenicity. For instance, MarA homologs in pathogens like *Salmonella* and *Klebsiella* influence virulence and antibiotic tolerance. Additionally, MarA’s overlap with other regulators (e.g., SoxS, Rob) in the "MarA regulon" highlights its integration into broader stress-response networks.
Efforts to inhibit MarA or its pathway aim to reverse antibiotic resistance, making it a potential therapeutic target. Structural insights from recombinant MarA (e.g., crystal structures of DNA-binding domains) guide drug design strategies. Overall, MarA recombinant protein serves as a critical tool for understanding bacterial resistance mechanisms and developing anti-resistance therapies.
×
